We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current TEV market cap is 18.03B. The company's latest EPS is USD -1.4455 and P/E is -10.29.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 16.66B | 15.88B | 14.93B | 15.85B | 16.54B |
| Operating Income | -3.58B | 1.71B | -2.12B | 408M | 724M |
| Net Income | -3.99B | 417M | -2.35B | -559M | -1.64B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 50.64B | 47.67B | 44.01B | 43.48B | 39.33B |
| Total Liabilities | 39.58B | 36.42B | 35.32B | 35.35B | 33.61B |
| Total Equity | 11.06B | 11.24B | 8.69B | 8.13B | 5.38B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 1.22B | 798M | 1.59B | 1.37B | 1.25B |
| Investing | 863M | 1.52B | 656M | 968M | 792M |
| Financing | -1.89B | -2.17B | -1.49B | -1.91B | -1.79B |
| Market Cap | 18.03B |
| Price to Earnings Ratio | -10.29 |
| Price to Sales Ratio | 1.02 |
| Price to Cash Ratio | 5.11 |
| Price to Book Ratio | 2.95 |
| Dividend Yield | - |
| Shares Outstanding | 1.13B |
| Average Volume (1 week) | 7.6k |
| Average Volume (1 Month) | 11.22k |
| 52 Week Change | 29.80% |
| 52 Week High | 22.00 |
| 52 Week Low | 11.50 |
| Spread (Intraday) | 0.3 (1.88%) |
| Company Name | Teva Pharmaceutical Industries Ltd |
| Address |
124 dvora hanevi’a st tel aviv, center 6944020 |
| Website | https://www.tevapharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
